SCHEMBL4967922

SCHEMBL4967922

C[C@](N)(O)CN1CCOCC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
RECQL P46063 1/20 0.44
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
USP2 O75604 1/20 0.40
KEAP1 Q14145 1/20 0.39
HSD17B10 Q99714 3/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALOX15 P16050 2/20 0.36
TSHR P16473 1/20 0.36
ANPEP P15144 1/20 0.36
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.35
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28819145 1.00 ALDH1A1 (0.44) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL862113 0.82 SMN1; SMN2 (0.41) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL6484208 0.82 ALDH1A1 (0.52) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
Hydrochloric Acid SCHEMBL17257995 0.80 SMN1; SMN2 (0.40) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL10153213 0.79 ALDH1A1 (0.40) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL10628686 0.79 KDM4E (0.41) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL9863949 0.78 ALDH1A1 (0.44) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL11640031 0.77 SMN1; SMN2 (0.38) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL179555 0.77 ALDH1A1 (0.41) ALDH1A1RECQLKDM4ESMN1; SMN2USP2
SCHEMBL872596 0.76 ALDH1A1 (0.38) ALDH1A1RECQLKDM4ESMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562600-A4 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS SUGEN INC (US) 2008-06-25 EP disclosed
EP-1446117-A4 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN INC (US) 2008-01-23 EP disclosed
EP-1599207-A2 TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS Sugen, Inc. (US) 2005-11-30 EP disclosed
EP-1562600-A2 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS Sugen, Inc. (US) 2005-08-17 EP disclosed
WO-2004075775-A2 TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2004-09-10 WO disclosed
EP-1446117-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS Sugen, Inc. (US) 2004-08-18 EP disclosed
WO-2004045523-A2 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS SUGEN, INC. (US) 2004-06-03 WO disclosed
EP-1370554-A1 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2003-12-17 EP disclosed
WO-2003035009-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2003-05-01 WO disclosed
WO-2002066463-A1 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2002-08-29 WO disclosed